DUBLIN, June 1, 2021 – Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced its virtual participation at the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking place June 2-5, 2021.
Medtronic will showcase clinically meaningful outcomes associated with the company’s comprehensive product portfolio and future technologies and customer-centric support and services provided in a remote environment during the COVID-19 pandemic, including onboarding and training for healthcare providers and patients.
Scientific Presentation: The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research. Poster presentations will be available to all attendees for viewing to query presenters throughout the conference.
About the Diabetes Business at the company:
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care, and improving outcomes, allowing people living with diabetes to enjoy greater freedom and better health.
About the company: Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s most influential medical technology, services, and solutions companies – alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in 150 countries. The company is focused on collaborating with stakeholders worldwide to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.